The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fodor, W.
Right arrow Articles by Squinto, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fodor, W.
Right arrow Articles by Squinto, S.

The Journal of Immunology, Vol 155, Issue 9 4135-4138, Copyright © 1995 by American Association of Immunologists

CUTTING EDGE

A novel bifunctional chimeric complement inhibitor that regulates C3 convertase and formation of the membrane attack complex

WL Fodor, SA Rollins, ER Guilmette, E Setter and SP Squinto
Department of Molecular Development, Alexion Pharmaceuticals, Inc., New Haven, CT 06511, USA.

Human cells express cell surface complement regulatory molecules that inhibit the activity of the C3/C5 convertases (DAF, MCP, CR1) or inhibit the membrane attack complex (CD59). A single molecule that inhibits both the convertase activity and formation of the membrane attack complex has never been characterized. To this end, we have developed two reciprocal chimeric complement inhibitors (CD, NH2-CD59- DAF-GPI; and DC, NH2-DAF-CD59-GPI) that contain the functional domains of decay accelerating factor (DAF; CD55) and CD59. Cell surface expression of the CD and DC chimeric proteins was detected with DAF- and CD59-specific antisera. Cell surface C3d deposition was inhibited on cells expressing the chimeric molecules, thereby indicating that the DAF moiety was functional in both molecules. Conversely, Ab-blocking experiments demonstrated that only the DC molecule retained CD59 function. Therefore, the DC molecule represents a novel potent chimeric bifunctional complement inhibitor that retains the functional domains of two distinct complement regulatory molecules.


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
S. I-H. Hsu and W. G. Couser
Chronic Progression of Tubulointerstitial Damage in Proteinuric Renal Disease Is Mediated by Complement Activation: A Therapeutic Role for Complement Inhibitors?
J. Am. Soc. Nephrol., July 1, 2003; 14(90002): S186 - 191.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
S. C. Makrides
Therapeutic Inhibition of the Complement System
Pharmacol. Rev., March 1, 1998; 50(1): 59 - 88.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H.-f. Zhang, S. Lu, S. L. Morrison, and S. Tomlinson
Targeting of Functional Antibody-Decay-accelerating Factor Fusion Proteins to a Cell Surface
J. Biol. Chem., July 13, 2001; 276(29): 27290 - 27295.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.